{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:33:49Z","timestamp":1771918429202,"version":"3.50.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Adherence to prescribed antipsychotics is an ongoing problem. Traditionally, estimates of adherence have been made from patient interviews, pill counting and blood testing. A number of methods for the analysis of antipsychotics in blood have been reported for both therapeutic drug monitoring and postmortem testing for toxicity. This report details a dilute and shoot method for the analysis of 19 different antipsychotics and metabolites. The method takes advantage of earlier reports demonstrating unique, prevalent urine metabolites for aripiprazole, brexpiprazole, haloperidol and lurasidone to enhance sensitivity for these analytes. With a fast analysis time and minimal sample preparation, this method can be used for quantitation of antipsychotics in urine. Finally, this method has been used to test samples for over a year with the results summarized in this report. While further improvements are certainly possible, this method is selective and sensitive for this group of important compounds.<\/jats:p>","DOI":"10.1093\/jat\/bkz098","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T20:11:36Z","timestamp":1574712696000},"page":"331-338","source":"Crossref","is-referenced-by-count":19,"title":["A Dilute and Shoot LC\u2013MS\/MS Method for Antipsychotics in Urine"],"prefix":"10.1093","volume":"44","author":[{"given":"Sheng","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R","family":"Enders","sequence":"first","affiliation":[{"name":"Molecular Education, Technology and Research Innovation Center (METRIC), Department of Biological Sciences, North Carolina State University, Raleigh, NC, 27695"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oneka T","family":"Cummings","sequence":"first","affiliation":[{"name":"Insource Diagnostics, 231 West Chestnut Ave., Monrovia, CA 91016, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin C","family":"Strickland","sequence":"first","affiliation":[{"name":"Research and Development, Ameritox, LLC, 486 Gallimore Dairy Rd, Greensboro, NC 27409, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"McIntire","sequence":"first","affiliation":[{"name":"Veterans Administration, 1 VA Center, Augusta, ME 04330, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"McIntire","sequence":"first","affiliation":[{"name":"Research and Development, Premier Biotech, 723 Kasota Ave SE, Minneapolis, MN 55414, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,11,27]]},"reference":[{"key":"2020051613280796400_ref1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/2045125312474019","article-title":"Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review","volume":"3","author":"Higashi","year":"2013","journal-title":"Therapeutic Advances in Psychopharmacology"},{"key":"2020051613280796400_ref2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1399-5618.2006.00314.x","article-title":"Treatment adherence with antipsychotic medications in bipolar disorder","volume":"8","author":"Sajatovic","year":"2006","journal-title":"Bipolar Disorders"},{"key":"2020051613280796400_ref3","first-page":"89","article-title":"Suboptimal treatment adherence in bipolar disorder: impact on clinical outcomes and functioning","volume":"7","author":"Montes","year":"2013","journal-title":"Patient Preference and Adherence"},{"key":"2020051613280796400_ref4","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-2-6","article-title":"Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia","author":"Asher-Svanum","year":"2009","journal-title":"BMC Research Notes"},{"key":"2020051613280796400_ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/217047","article-title":"Medication adherence measure: an overview","author":"Lam","year":"2015","journal-title":"BioMed Research International"},{"key":"2020051613280796400_ref6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.forsciint.2013.02.010","article-title":"LC\u2013MS\/MS of some atypical antipsychotics in human plasma, serum, oral fluid and haemolysed whole blood","volume":"229","author":"Fisher","year":"2013","journal-title":"Forensic Science International"},{"key":"2020051613280796400_ref7","first-page":"28","article-title":"Determination of drugs in plasma samples by high-performance liquid chromatography\u2013tandem mass spectrometry for therapeutic drug monitoring of schizophrenic patients","volume":"40","author":"Damingues","year":"2016","journal-title":"Journal of Analytical Toxicology"},{"key":"2020051613280796400_ref8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/jat\/32.2.147","article-title":"Quantitation of seven low-dosage antipsychotic drugs in human postmortem blood using LC\u2013MS\u2013MS","volume":"32","author":"Roman","year":"2008","journal-title":"Journal of Analytical Toxicology"},{"key":"2020051613280796400_ref9","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/jms.1783","article-title":"Identification and quantification of 30 antipsychotics in blood using LC\u2013MS\/MS","volume":"45","author":"Saar","year":"2010","journal-title":"Journal of Mass Spectrometry"},{"key":"2020051613280796400_ref10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.chc.2016.02.005","article-title":"Objective testing: urine and other drug tests","volume":"25","author":"Hadland","year":"2016","journal-title":"Child and Adolescent Psychiatric Clinics of North America"},{"key":"2020051613280796400_ref11","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1007\/s00213-014-3781-1","article-title":"Quantitative levels of aripiprazole parent drug and metabolites in urine","volume":"231","author":"McEvoy","year":"2014","journal-title":"Psychopharmacology"},{"key":"2020051613280796400_ref12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clinms.2017.11.001","article-title":"Identification of metabolites of brexpiprazole in human urine for use in monitoring patient compliance","volume":"6","author":"Enders","year":"2017","journal-title":"Clinical Mass Spectrometry"},{"key":"2020051613280796400_ref13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jat\/bkx103","article-title":"Impact of \u03b2-glucuronidase mediated hydrolysis on Haldol\u00ae urinalysis","volume":"42","author":"Cummings","year":"2018","journal-title":"Journal of Analytical Toxicology"},{"key":"2020051613280796400_ref14","first-page":"8","article-title":"Determination of the relative prevalence of lurasidone metabolites in urine using untargeted HRMS","volume":"17","author":"Strickland","year":"2019","journal-title":"Current Trends in Mass Spectrometry"},{"key":"2020051613280796400_ref15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/jat\/bkw078","article-title":"Impact of monitoring quetiapine carboxylic acid and quetiapine sulfoxide on patient positivity by urine drug testing","volume":"40","author":"Strickland","year":"2016","journal-title":"Journal of Analytical Toxicology"},{"key":"2020051613280796400_ref16","volume-title":"Manual for Urine Laboratories","author":"National Laboratory Certification Program (NLCP)","year":"2010"},{"key":"2020051613280796400_ref17","volume-title":"Guidance for Industry: Bioanalytical Method Validation","author":"U.S. Department of Health and Human Services","year":"2001"},{"key":"2020051613280796400_ref18","volume-title":"CLIA\u2014Compliant Analytical Method Validation Plan and Template for LRN-C Laboratories","author":"Association of Public Health Laboratories","year":"2013"},{"key":"2020051613280796400_ref19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.forsciint.2006.05.021","article-title":"Validation of new methods","volume":"165","author":"Peters","year":"2007","journal-title":"Forensic Science International"},{"key":"2020051613280796400_ref20","first-page":"114","volume-title":"Principles of Forensic Toxicology","author":"Levine","year":"2003","edition":"2nd"},{"key":"2020051613280796400_ref21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/jat\/bkv087","article-title":"A dilute-and-shoot LC\u2013MS method for quantitating opioids in oral fluid","volume":"39","author":"Enders","year":"2015","journal-title":"Journal of Analytical Toxicology"},{"key":"2020051613280796400_ref22","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.cpem.2012.09.005","article-title":"Adverse effects and toxicity of the atypical antipsychotics: what is important for the pediatric emergency medicine practitioner","volume":"13","author":"Rasimis","year":"2012","journal-title":"Clinical Pediatric Emergency Medicine"},{"key":"2020051613280796400_ref23","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/15563650701665142","article-title":"Atypical antipsychotic medication poisoning: an evidence-based consensus guideline for out-of-hospital management","volume":"45","author":"Cobaugh","year":"2007","journal-title":"Clinical Toxicology"},{"key":"2020051613280796400_ref24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/mas.20298","article-title":"An overview of matrix effects in liquid chromatography\u2013mass spectrometry","volume":"30","author":"Trufelli","year":"2011","journal-title":"Mass Spectrometry Reviews"},{"key":"2020051613280796400_ref25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1046\/j.1365-2125.1998.00770.x","article-title":"Best practice in therapeutic drug monitoring","volume":"46","author":"Gross","year":"1998","journal-title":"British Journal of Clinical Pharmacology"},{"key":"2020051613280796400_ref26","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1124\/dmd.110.036715","article-title":"Metabolism and excretion of asenapine in healthy male subjects","volume":"39","author":"Van de Wetering-Krebbers","year":"2011","journal-title":"Drug Metabolism & Disposition"},{"key":"2020051613280796400_ref27","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2215\/CJN.00340118","article-title":"Clinical pharmacokinetics in kidney disease: fundamental principles","volume":"13","author":"Lea-Henry","year":"2018","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"2020051613280796400_ref28","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.gpb.2016.03.008","article-title":"Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine","volume":"14","author":"Ahmed","year":"2016","journal-title":"Genomics, Proteomics & Bioinformatics"},{"key":"2020051613280796400_ref29","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1373\/jalm.2017.023663","article-title":"Positive urine paliperidone test results in absence of prescribed medication","volume":"2","author":"Su","year":"2017","journal-title":"The Journal of Applied Laboratory Medicine"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkz098\/32989292\/bkz098.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jat\/article-pdf\/44\/4\/331\/33220900\/bkz098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jat\/article-pdf\/44\/4\/331\/33220900\/bkz098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T21:11:43Z","timestamp":1589663503000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/44\/4\/331\/5644224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,27]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,11,27]]},"published-print":{"date-parts":[[2020,5,18]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkz098","relation":{},"ISSN":["0146-4760","1945-2403"],"issn-type":[{"value":"0146-4760","type":"print"},{"value":"1945-2403","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2019,11,27]]}}}